Evaluation of Serum Metalloprotinase-9 (MMP-9) in Iraqi Men with urinary tract infection

2017 ◽  
Vol 6 (12) ◽  
pp. 5558
Author(s):  
Hanan D. Abbas
Keyword(s):  
United States ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
United States Of America ◽  
Prognostic Biomarker ◽  
The United States ◽  
Control Group ◽  
Strong Relation ◽  
Tract Infections

Objective: The inflammation of the urinary tract and its various causes is one of the important diseases, which neglect and non-treatment lead to many amplifications, therefore, many countries including the United States of America has given urinary tract infection ″UTI″ a great interest. Since the disease is sometimes without obvious symptoms and because of research lacking that are using MMP-9. The aim of this work is to study the alterations in the Metalloprotinase-9 (MMP-9), and its role in pathogenicity of urinary tract infections ″UTI″ in serum of men who are initially diagnosed with this disease.Methods: This study was applied in educational Alsader hospital in Najaf city by using Enzyme Linked Immuno Sorbent Assay (ELISA) on serum taken from 42 men infected with UTI, and other 38 healthy considered as a control group to detect MMP-9.Data analysis: SPSS computerizing system has been used for statistically analysis of data. Results: The results revealed a highly significant (P<0. 05) level of ″MMP-9″in serum of patients in comparison with the control group. The result also demonstrated the strong relation between MMP-9 and other parameters such as age and smoking.Conclusion: It was concluded from the results of the present study thatMetalloprotinase-9″MMP-9″ was good prognostic biomarker for ″UTI″ in men, and these results significantly correlate with the early stages of disease.Recommendation: 1-It may be recommended that using MMP-9 to predict and diagnosis the urinary tract infection. 2-It may be also recommended to measure MMP-9 in women to establish its role in this disease 

scholarly journals An Unusual Case:SalmonellaUTI and Orchitis in HIV Patient

2015 ◽  
Vol 2015 ◽  
pp. 1-2
Author(s):  
Sabrina Arshed ◽  
Hongxiu Luo ◽  
John Middleton ◽  
Abdalla Yousif
Keyword(s):  
Diabetes Mellitus ◽  
United States ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Critical Illness ◽  
Tract Infection ◽  
Young Male ◽  
The United States ◽  
Immune Deficiencies ◽  
Tract Infections

Salmonellosis is a major cause of gastroenteritis in the United States; however, nontyphoidal strains ofSalmonellahave also been known to cause urinary tract infections, usually transmitted via the fecal-urethral route. This can lead to critical illness in those patients with immune deficiencies, especially HIV, cancer patients, and those with diabetes mellitus. However, the spread of the infection from the urinary tract to involve the testicles and epididymis is very rare. Here, we present the first documented case of an immune-compromised young male with a urinary tract infection with orchitoepididymitis.

scholarly journals Preventing Hospital-Acquired Urinary Tract Infection in the United States: A National Study

2008 ◽  
Vol 46 (2) ◽  
pp. 243-250 ◽  
Author(s):  
S. Saint ◽  
C. P. Kowalski ◽  
S. R. Kaufman ◽  
T. P. Hofer ◽  
C. A. Kauffman ◽  
...  
Keyword(s):  
United States ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
The United States ◽  
National Study ◽  
Hospital Acquired

scholarly journals 1367. Clinical Cure in Secondary Efficacy Populations in Patients With Complicated Urinary Tract Infection Treated With ZTI-01 (Fosfomycin for Injection): Findings From the ZEUS Trial

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S418-S419 ◽  
Author(s):  
Keith Kaye ◽  
Louis B Rice ◽  
Viktor Stus ◽  
Olexsiy Sagan ◽  
Elena Fedosiuk ◽  
...  
Keyword(s):  
United States ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Clinical Cure ◽  
Complicated Urinary Tract Infection ◽  
The United States ◽  
Research Support ◽  
Gram Negative ◽  
Cure Rates

Abstract Background ZTI-01 (fosfomycin for injection) is an investigational epoxide antibiotic with a differentiated mechanism of action (MOA) inhibiting an early step in bacterial cell wall synthesis. ZTI-01 has a broad spectrum of in vitro activity, including multidrug-resistant Gram-negative pathogens, and is being developed for the treatment of patients with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) in the United States. Methods ZEUS was a multicenter, double-blind, Phase 2/3 trial in hospitalized adults with cUTI and AP to evaluate safety and efficacy. Randomized patients received 6 g ZTI-01 q8h or 4.5 g IV piperacillin/tazobactam (PIP-TAZ) q8h for 7 days; patients with baseline bacteremia could receive up to 14 days; study continued to late follow-up (LFU, 26 ± 2 days). Oral step-down therapy was prohibited. ZTI-01 met the primary endpoint of noninferiority to PIP-TAZ. Secondary objectives included comparing clinical cure rates (assessed by investigator) in the modified intent-to-treat (MITT), microbiologic MITT (m-MITT), clinical evaluable (CE), and microbiologic evaluable (ME) populations at test-of-cure (TOC, Day 19 ± 2 days). Results There were 464 patients randomized who received study drug. In all populations, clinical cure rates at TOC were high and similar between treatment groups (&gt;90%) (table). Conclusion These results demonstrate consistent efficacy in multiple secondary efficacy populations for patients with cUTI and AP who were treated with either ZTI-01 or PIP-TAZ. If approved by FDA, ZTI-01 may provide a new IV option with a differentiated MOA for patients in the United States with serious Gram-negative infections. 95% confidence intervals (CIs, two-sided) were computed using a continuity-corrected Zstatistic. Disclosures K. Kaye, Zavante Therapeutics, Inc.: Scientific Advisor, Consulting fee. L. B. Rice, Zavante Therapeutics, Inc.: Scientific Advisor, Consulting fee. V. Stus, Zavante Therapeutics, Inc.: Investigator, Research support. O. Sagan, Zavante Therapeutics, Inc.: Investigator, Research support. E. Fedosiuk, Zavante Therapeutics, Inc.: Investigator, Research support. A. Das, Zavante Therapeutics, Inc.: Consultant, Consulting fee. D. Skarinksy, Zavante Therapeutics, Inc.: Employee and Shareholder, Salary. P. B. Eckburg, Zavante Therapeutics, Inc.: Consultant and Shareholder, Consulting fee. K. Manvelian, Zavante Therapeutics, Inc.: Employee and Shareholder, Salary. E. J. Ellis-Grosse, Zavante Therapeutics, Inc.: Employee and Shareholder, Salary.

scholarly journals Preventing Catheter-Associated Urinary Tract Infection in the United States

2013 ◽  
Vol 173 (10) ◽  
pp. 874 ◽  
Author(s):  
Sanjay Saint ◽  
M. Todd Greene ◽  
Christine P. Kowalski ◽  
Sam R. Watson ◽  
Timothy P. Hofer ◽  
...  
Keyword(s):  
United States ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
The United States

scholarly journals COMPARATION OF EFFECTIVENESS OF NORMAL SALINE AND 10% POVIDONE IODINE IN PERIURETHRAL CLEANING

2016 ◽  
Vol 1 (1) ◽  
Author(s):  
Awaluddin Awaluddin
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Normal Saline ◽  
Povidone Iodine ◽  
Urinary Catheter ◽  
Infection Risk ◽  
Control Group ◽  
Tract Infections ◽  
Indwelling Urinary Catheter

Currently, urinary tract infection incidence in patients with indwelling urinary catheter ranges between 10-80%. They are at risk for other problems that can cause death. Appropriate action is required to decrease urinary tract infection risk by periurethral area cleaning. The aim of this study is to analyze the differences of the effectiveness of the use of normal saline and 10% povidone iodine for periurethral area cleaning in decreasing urinary tract infection risk. Research methods uses experimental design with the population of patients who used indwelling urinary catheter. Samples were obtained by consecutive and allocation by randomization which were divided into 2 groups, each group were 17 respondents. In the treatment group, periurethral area was cleaned with normal saline and in the control group with 10% povidone iodine. Urinary tract infection risk assessment was carried out by the leukocyte esterase dipstick test at 8 hours after insertion. The results indicate that the incidence of urinary tract infections risk in the group using normal saline smaller than 10% povidone iodine  with a comparison of 1:1.3. Number need to treat in this study was 6. The conclusion of this study is normal saline is more effective in reducing urinary tract infection risk.

scholarly journals COMPARATION OF EFFECTIVENESS OF NORMAL SALINE AND 10% POVIDONE IODINE IN PERIURETHRAL CLEANING

2016 ◽  
Vol 1 (1) ◽  
Author(s):  
Awaluddin Awaluddin
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Normal Saline ◽  
Povidone Iodine ◽  
Urinary Catheter ◽  
Infection Risk ◽  
Control Group ◽  
Tract Infections ◽  
Indwelling Urinary Catheter

Currently, urinary tract infection incidence in patients with indwelling urinary catheter ranges between 10-80%. They are at risk for other problems that can cause death. Appropriate action is required to decrease urinary tract infection risk by periurethral area cleaning. The aim of this study is to analyze the differences of the effectiveness of the use of normal saline and 10% povidone iodine for periurethral area cleaning in decreasing urinary tract infection risk. Research methods uses experimental design with the population of patients who used indwelling urinary catheter. Samples were obtained by consecutive and allocation by randomization which were divided into 2 groups, each group were 17 respondents. In the treatment group, periurethral area was cleaned with normal saline and in the control group with 10% povidone iodine. Urinary tract infection risk assessment was carried out by the leukocyte esterase dipstick test at 8 hours after insertion. The results indicate that the incidence of urinary tract infections risk in the group using normal saline smaller than 10% povidone iodine  with a comparison of 1:1.3. Number need to treat in this study was 6. The conclusion of this study is normal saline is more effective in reducing urinary tract infection risk.

scholarly journals Faecal Escherichia coli from patients with E. coli urinary tract infection and healthy controls who have never had a urinary tract infection

2014 ◽  
Vol 63 (4) ◽  
pp. 582-589 ◽  
Author(s):  
Karen L. Nielsen ◽  
Pia Dynesen ◽  
Preben Larsen ◽  
Niels Frimodt-Møller
Keyword(s):  
Escherichia Coli ◽  
Urinary Tract Infection ◽  
Multidrug Resistance ◽  
Urinary Tract ◽  
Tract Infection ◽  
Control Group ◽  
Healthy Controls ◽  
Faecal Flora ◽  
E Coli ◽  
Tract Infections

Urinary tract infections (UTIs) are primarily caused by Escherichia coli with the patient’s own faecal flora acting as a reservoir for the infecting E. coli. Here we sought to characterize the E. coli faecal flora of UTI patients and healthy controls who had never had a UTI. Up to 20 E. coli colonies from each rectal swab were random amplified polymorphic DNA (RAPD) typed for clonality, dominance in the sample and correlation to the infecting UTI isolate in patients. Each distinct clone was phylotyped and tested for antimicrobial susceptibility. Eighty-seven per cent of the UTI patients carried the infecting strain in their faecal flora, and faecal clones causing UTI were more often dominant in the faecal flora. Patients had a larger diversity of E. coli in their gut flora by carrying more unique E. coli clones compared to controls, and patient faecal clones were more often associated with multidrug resistance compared to controls. We found a similar phylotype distribution of faecal clones from UTI patients and healthy controls, including a large proportion of B2 isolates in the control group. Faecal-UTI isolates from patients were more often associated with multidrug resistance compared to faecal-only clones, indicating a link between UTI virulence and antimicrobial resistance. Intake of any antibiotic less than 6 months prior to inclusion in the experiment occurred significantly more in patients with UTI than in controls. In contrast, presence of an intrauterine device was significantly more common in controls indicating a protective effect against UTI. In conclusion, healthy controls have a large proportion of potentially pathogenic E. coli phylotypes in their faecal flora without this causing infection.

Sign in / Sign up

Export Citation Format

Share Document